Mateon and Oncotelic Complete Their Merger and Create a New Immuno-Oncology Company with a Late-Stage Clinical Asset Against Cancer and a Promising Product Pipeline

    NEXT STORY
    NeuroMetrix Reports Q1 2019 Financial Results
    PREV STORY
    Decision by the Board of Directors to acquire own shares
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

    author_avatar
    NASDAQ Market News

    “After the Smoke Clears” Brings Hope to Community on the Heels of Mental Health Awareness Month

    author_avatar
    NASDAQ Market News

    MacroGenics to Host 2016 R&D Day

    ROCKVILLE, MD, Dec. 08, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical ...

    author_avatar
    NASDAQ Market News